The short version of pentapeptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-21 and is reviewed periodically as new material appears.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Includes two non-natural residues |
| Molecular weight | About 711.9 g/mol | Confirmed by mass spectrometry |
| Appearance | White to off-white powder | Typical lyophilized form |
| Receptor target | GHS-R1a | Ghrelin receptor agonist |
| Plasma half-life | Roughly 2 hours | Varies by species and assay |
Mass spectrometry confirms identity and reveals structural deviations that chromatography alone can miss. Positive-mode electrospray ionisation generally yields multiply charged ions whose deconvoluted mass is checked against the theoretical value. Amino acid analysis, and enzymatic digestion with subsequent fragment mapping, provide independent confirmation of sequence and of the terminal amide. Analysts take care to separate the target from deletion sequences, which may differ by one residue and therefore by only a small mass increment.
The lyophilised solid is normally held at -20 °C or colder, shielded from light and moisture. Stability in that state is measured in years, although shelf life depends on residual water content and the container seal. Once dissolved, the peptide is more fragile: aqueous solutions are commonly kept at 2-8 °C and used within days to weeks, and repeated freeze-thaw cycling is avoided. Strongly acidic or basic conditions accelerate hydrolysis, and prolonged exposure to them can strip the terminal amide.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.
Common solvents for laboratory work include water, buffered saline, and dimethyl sulfoxide. Once dissolved, the peptide is exposed to hydrolysis and oxidation, and alkaline conditions accelerate breakdown. Low-binding plasticware and the addition of a carrier protein reduce losses to container surfaces, which can otherwise be substantial at low concentrations. Solutions are typically kept cold and used within days. Investigators working with the compound generally prepare fresh working dilutions rather than storing dilute stocks, and they avoid repeated warming of the same vial.
Muscle contraction stimulates muscle cells to translocate GLUT4 receptors to their surfaces. This is especially true in cardiac muscle, where continuous contraction increases the rate of GLUT4 translocation; but is observed to a lesser extent in increased skeletal muscle contraction. In skeletal muscle, muscle contractions substantially increase GLUT4 translocation, which is regulated by RAC1 and AMP-activated protein kinase (AMPK). Contraction-induced glucose uptake involves the phosphorylation of RabGaps, TBC1D1 and TBC1D4, by AMPK and other kinases such as SNARK. This mechanism remains functional in insulin-resistant states, establishing the muscle-contraction pathway's independence from insulin stimulation. The figure to the right demonstrates how insulin- and contraction-stimulated GLUT4 translocation differ but ultimately converge on TBC1D1/4. Phosphorylation of TBC1D1/4 inactivates it, allowing Rab proteins to load GTP and directly participate in the trafficking of GLUT4 to the membrane. AMPK plays a crucial role in the contraction pathway. ATP is known as an energy-sensing enzyme, as it's highly responsive to an increase in the AMP to ATP ratio. ATP is hydrolyzed to ADP during muscle contraction by actomyosin ATPase. Adenylate kinase subsequently converts ADP through the following reaction: 2ADP→ATP+AMP. This ensures rapid replenishment of ATP, while increasing AMP concentration. ATP competes with AMP for coupling to the AMPK binding domain and thus inhibits AMPK activity, particularly when the muscle is at rest and ATP concentration is high.
=== World Anti-Doping Agency === World Anti-Doping Agency (WADA) is the foundation made by the International Olympic Committee in 1999 and its role is to promote, coordinate and monitor drug use within sports. WADA is responsible for the creation of the World Anti-Doping Code which is adopted by more than 600 sporting organizations. The main tasks that the agency are involved in are research, education, development of anti-doping bodies and regulating the World Anit-Doping Code. Recently, WADA has developed partnerships with pharmaceutical and biotechnology companies with the aim to try to facilitate drug detection methods.
Pheromone Endorphins Anaphrodisiac Date rape drug Entactogen Food and sexuality Fork Me, Spoon Me, 2006 book Hypersexuality Hypoactive sexual desire disorder List of investigational sexual dysfunction drugs Love potion Phytoestrogen Phytoandrogen Androgens Estrogens Viagra Vyleesi
Sources: en.wikipedia.org
Chain-ganging occurs when a state sees its own security tied to the security of its alliance partner. It chains itself by deeming any attack on its ally the equivalent of an attack on itself. That is another aspect of the balance of power theory, whereby the smaller states could drag their chained states into wars that they have no desire to fight. A key example was the chain-ganging between states prior to World War I, dragging most of Europe to war over a dispute between the relatively major power of Austria-Hungary and the minor power of Serbia. Thus, states "may chain themselves unconditionally to reckless allies whose survival is seen to be indispensable to the maintenance of the balance".
An alternative model, proposed by politicians in Oldenburg and Brunswick, envisaged the foundation of the independent state of "Weser-Ems", that would be formed from the state of Oldenburg, the Hanseatic City of Bremen and the administrative regions of Aurich and Osnabrück. Several representatives of the state of Oldenburg even demanded the inclusion of the Hanoverian districts of Diepholz, Syke, Osterholz-Scharmbeck and Wesermünde in the proposed state of "Weser-Ems". Likewise an enlarged State of Brunswick was proposed in the southeast to include the Regierungsbezirk of Hildesheim and the district of Gifhorn. Had this plan come to fruition, the territory of the present Lower Saxony would have consisted of three states of roughly equal size. The district council of Vechta protested on 12 June 1946 against being incorporated into the metropolitan area of Hanover (Großraum Hannover). If the State of Oldenburg was to be dissolved, Vechta District would much rather be included in the Westphalian region. Particularly in the districts where there was a political Catholicism the notion was widespread, that Oldenburg Münsterland and the Regierungsbezirk of Osnabrück should be part of a newly formed State of Westphalia. Since the foundation of the states of North Rhine-Westphalia and Hanover on 23 August 1946 the northern and eastern border of North Rhine-Westphalia has largely been identical with that of the Prussian Province of Westphalia. Only the Free State of Lippe was not incorporated into North Rhine-Westphalia until January 1947.
Lactation suppression Hyperprolactinemia Adjunctive therapy of prolactin-producing pituitary gland tumors (prolactinomas); Monotherapy of Parkinson's disease in the early phase; Combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson's disease; In some countries also: ablactation and dysfunctions associated with hyperprolactinemia (amenorrhea, oligomenorrhea, anovulation, nonpuerperal mastitis and galactorrhea); Treatment of uterine fibroids. Adjunctive therapy of acromegaly: Cabergoline has low efficacy in suppressing growth hormone levels and is highly efficient in suppressing hyperprolactinemia, which is present in 20–30% of acromegaly cases. Growth hormone and prolactin are similar structurally and have similar effects in many target tissues; therefore, targeting prolactin may help symptoms when growth hormone secretion cannot be sufficiently controlled by other methods. Cabergoline is frequently used as a first-line agent in the management of prolactinomas due to its higher affinity for D2 receptor sites, less severe side effects, and more convenient dosing schedule than the older bromocriptine, though in pregnancy bromocriptine is often still chosen since there is less data on safety in pregnancy for cabergoline.
CPC offers direct scale-up from analytical apparatuses (few milliliters) to industrial apparatuses (several liters) for fast batch-production. CPC seems particularly suited to accommodate aqueous two-phase solvent systems. Generally, CPC instruments can retain solvent systems that are not well-retained in a hydrodynamic instrument due to small differences in density between the phases. It has been very helpful for the development of CPC instrumentation to visualize the flow patterns which give rise to the mixing and settling in the CPC chamber with an asynchronous camera and a stroboscope triggered by the CPC rotor. The aforementioned hydrodynamic and hydrostatic instruments may be employed in a variety of ways, or modes of operation, in order to address the particular separation needs of the scientist. Many modes of operation have been devised to take advantage of the strengths and potentialities of the countercurrent chromatography technique. Generally, the following modes may be performed with commercially available instruments.
Sources: en.wikipedia.org
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.
It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.
No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.
It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.